Tarsus Pharmaceuticals, Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Revenues:
Cost of sales $42.8m $955k $1.6m $12.8m $30.7m
Research and development $3.2m $18.8m $41.7m $42.6m $50.3m $53.4m $64.3m
Selling, general and administrative $44.9m $108.7m $237.3m $427.3m
Total operating expenses $4.3m $27.0m $69.2m $88.5m $160.6m $303.5m $522.3m
Interest income $188k $36k $3.5m $10.3m $15.0m $15.7m
Loss on debt extinguishment ($255k) $0 $0 $0 ($1.9m) $0
Loss before income taxes ($26.8m) ($13.8m) ($62.1m) ($135.9m) ($115.6m) ($64.4m)
Provision for income taxes ($1k) ($1k) ($55k) $4k $0 $0 ($2.1m)
Net loss ($4.7m) ($26.8m) ($13.8m) ($62.1m) ($135.9m) ($115.6m) ($66.4m)
Unrealized gain (loss) on marketable securities and cash equivalents $0 ($74k) $72k $181k $202k
Comprehensive loss ($4.7m) ($26.8m) ($13.8m) ($62.2m) ($135.8m) ($115.4m) ($66.2m)
Total other income, net ($371k) $188k ($1.6m) $617k $7.3m $5.0m $6.6m
Net loss per share, basic (usd per share) ($2) ($4) ($1) ($3) ($5) ($3) ($2)
Net loss per share, diluted (usd per share) ($2) ($4) ($1) ($3) ($5) ($3) ($2)
Weighted-average shares outstanding, basic (in shares) 6.2m 20.6m 24.6m 29.4m 37.6m 41.8m
Weighted-average shares outstanding, diluted (in shares) 6.2m 20.6m 24.6m 29.4m 37.6m 41.8m
Loss from operations before other income (expense) ($4.3m) ($27.0m) ($12.2m) ($62.7m) ($143.2m) ($120.6m) ($71.0m)
Interest expense $0 ($2.2m) ($3.3m) ($7.8m) ($8.9m)
Other income (expense), net $0 ($73k) $86k ($102k) $586k ($202k)